- Home
- MGLD vs ARMP Comparison
MGLD vs ARMP Comparison
Compare MGLD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- ARMP
- Stock Information
- Founded
- MGLD 1996
- ARMP N/A
- Country
- MGLD United States
- ARMP United States
- Employees
- MGLD N/A
- ARMP N/A
- Industry
- MGLD Finance/Investors Services
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGLD Finance
- ARMP Health Care
- Exchange
- MGLD Nasdaq
- ARMP Nasdaq
- Market Cap
- MGLD 80.3M
- ARMP 80.0M
- IPO Year
- MGLD N/A
- ARMP N/A
- Fundamental
- Price
- MGLD $1.71
- ARMP $2.06
- Analyst Decision
- MGLD
- ARMP Strong Buy
- Analyst Count
- MGLD 0
- ARMP 1
- Target Price
- MGLD N/A
- ARMP $7.00
- AVG Volume (30 Days)
- MGLD 24.6K
- ARMP 13.8K
- Earning Date
- MGLD 02-12-2025
- ARMP 11-13-2024
- Dividend Yield
- MGLD N/A
- ARMP N/A
- EPS Growth
- MGLD N/A
- ARMP N/A
- EPS
- MGLD N/A
- ARMP N/A
- Revenue
- MGLD $32,511,000.00
- ARMP $5,467,000.00
- Revenue This Year
- MGLD N/A
- ARMP $23.87
- Revenue Next Year
- MGLD N/A
- ARMP N/A
- P/E Ratio
- MGLD N/A
- ARMP N/A
- Revenue Growth
- MGLD N/A
- ARMP 34.92
- 52 Week Low
- MGLD $0.78
- ARMP $1.80
- 52 Week High
- MGLD $2.10
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- MGLD 51.19
- ARMP 49.88
- Support Level
- MGLD $1.64
- ARMP $1.97
- Resistance Level
- MGLD $1.99
- ARMP $2.28
- Average True Range (ATR)
- MGLD 0.20
- ARMP 0.14
- MACD
- MGLD -0.02
- ARMP 0.01
- Stochastic Oscillator
- MGLD 23.68
- ARMP 54.17
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.